Senzime for investors
Investor event from Nov 15
We hosted a digital investor event for investors, financial analysts and media on November 15.
Guidelines from European Society of Anaesthesiology and Intensive Care
New European guidelines for quantitative neuromuscular monitoring
The guidelines include strong recommendations of using quantitative neuromuscular monitoring and to continue quantitative monitoring of neuromuscular blockade until a TOF ratio of more than 0.9 has been achieved.
TetraGraph enables all of this, supporting neuromuscular blockade management from start to finish.
A Swedish medical device company
Senzime develops, manufactures and markets CE- and FDA-cleared patient monitoring systems.
Our vision is a world without anesthesia and respiratory-related complications.
CEO Statement
Accelerating sales growth in the US and Europe, strategic partnership with global leader and acquisition in the US
Pia Renaudin
CEO